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6-Pyruvoyl-tetrahydropterin synthase (PTPS) deficiency results in depletion 
of the brain neuro-transmitters serotonin and dopamine. Since dopamine is the 
physiological inhibitor of pituitary prolactin secretion, hyperprolactinemia is 
common in patients with PTPS deficiency.  Serum prolactin concentrations are 
used for the monitoring and optimization of L-Dopa therapy. We report three 
adult patients with PTPS deficiency who had persistent hyperprolactinemia 
unresponsive to high dose L-Dopa therapy, and pituitary imaging confirmed 
microadenoma. In the presence of prolactinoma, serum prolactin is an 
unreliable tool for treatment monitoring in these patients. This report 
emphasizes the need to exclude other causes of hyperprolactinemia including 
prolactinoma, in patients who are compliant with optimized L-Dopa treatment 
and their prolactin levels remain significantly high.
Introduction
6-Pyruvoyl-tetrahydropterin synthase (PTPS) deficiency (MIM: 
261640), an autosomal recessive inherited metabolic disorder, is 
the most common cause of tetrahydrobiopterin (BH4) deficient 
hyperphenylalaninemia. PTPS has an important role in the synthesis 
of BH4, which is an essential cofactor for a group of enzymes 
including phenylalanine hydroxylase, tyrosine and tryptophan 
hydroxylases. BH4 deficiency results in impaired hydroxylation of 
phenylalanine to tyrosine, tyrosine into L-Dopa and tryptophan 
into 5-hydroxytryptophan. PTPS deficiency, therefore, leads to 
hyperphenylalaninemia and depletion of the brain neurotransmitters 
serotonin and dopamine1. This disorder is relatively common in 
Saudi Arabia due to a founder tribal mutation2, 3. It mostly presents 
in infancy with developmental delay, seizures, and abnormal 
movements associated with hyperphenylalaninemia. The diagnosis 
is made by abnormal urinary pterin metabolites (low biopterin 
and high neopterin), reduced levels of cerebrospinal fluid (CSF) 
neurotransmitters homovanillic acid (HVA) and 5-hydroxy indoleacetic 
acid (5-HIAA) and the presence of a pathogenic mutation in the PTS 
gene. Management of PTPS deficiency includes administration of 
synthetic BH4, and neurotransmitter replacement therapy with L-3,4-
dihydroxyphenylalanine (L-Dopa) and 5- hydroxytryptophan. Clinical 
monitoring of this treatment may be compromised by the side-effects 
of L-Dopa and 5-hydroxytryptophan, a presentation which can also 
mimic the symptoms of their deficiency and therefore treatment is 
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residual dystonia and abnormal behavior with poor social 
and communication skills. She had primary amenorrhea 
and associated osteoporosis treated with alendronate. The 
amenorrhea due to hypogonadotrophic hypogonadism 
was likely secondary to persistent hyperprolactinemia. 
Her serum prolactin concentrations remained high despite 
high dose L-Dopa (10.5 mg/kg body weight/day). Adequate 
dopamine replacement was consistent with satisfactory 
CSF neurotransmitter concentrations (Table 1). MRI scan of 
pituitary gland showed a 3 mm microadenoma (Figure 1a). 
At the age of 29 year, she was referred to the endocrinologist 
and was started on cabergoline 0.5 mg twice weekly. Serum 
prolactin levels normalized and menstrual periods began. 
Cabergoline was stopped after six months and she continues 
to have menstruation. Serum prolactin concentrations, 
however, are gradually rising, the latest being 308 µg/L. 
A repeat pituitary gland MRI after a two year interval re-
demonstrated unchanged microadenoma.
Case 2 
This 29-year-old female is the younger sister of case 1. 
She was born by caesarian section because of decreased 
fetal movement at 34 weeks of gestation. Her birth weight 
was 2.1 kg. PTPS deficiency was diagnosed on a newborn 
screen with hyperphenylalaninemia and a typical urine 
biopterin-neopterin profile. She was started on BH4 
supplement, L-Dopa and 5-hydroxytryptophan in the 
neonatal period. She has a mild intellectual disability. She 
was noted to have hyperprolactinemia therefore, the dose 
of L-Dopa was gradually increased to 13 mg/kg body weight 
daily. However, serum prolactin concentration remained 
very high, the likely cause of primary amenorrhea due 
to hypogonadotropic hypogonadism (Table 1). Pituitary 
monitored by serum prolactin and CSF neurotransmitters 
concentrations.  
Dopamine is the major physiological inhibitor of 
pituitary prolactin secretion and its deficiency results in 
mild to moderate hyperprolactinemia in patients with PTPS 
deficiency. It is secreted by the hypothalamus, and delivered 
to anterior pituitary via hypothalamohypophyseal blood 
circulation. Dopamine exerts its inhibitory role by binding 
to D2 and D4 receptors in the pituitary lactotrophs leading 
to down-regulation of prolactin gene expression, reduced 
prolactin secretion, and decreased lactotroph proliferation 
4, 5. Serum prolactin concentrations are inversely related 
to concentrations of CSF- HVA (a dopamine metabolite) 
and are, therefore, used as a biochemical marker for 
optimization of L-Dopa therapy in these patients 6- 8.  Here 
we report three adult patients with PTPS deficiency with 
persistent marked hyperprolactinemia unresponsive to 
high dose L-Dopa therapy, and subsequent pituitary gland 
MRI revealed microadenoma.
Case 1 
A 31-year-old female was born preterm at 32 weeks of 
gestation. Her birth weight was 1.75 kg. She had a normal 
post-natal course. At the age of 4 months, she was noted to 
have hypotonia which led to the diagnosis of PTPS deficiency 
based on high plasma phenylalanine levels, its response to 
BH4 loading test, low biopterin with high neopterin levels 
in urine and subsequently confirmed by genetic analysis. 
Following diagnosis, she was treated with BH4 supplement, 
L-Dopa (Sinemet) and 5-hydroxytryptophan. In childhood, 
she developed seizures and acute dystonia which were treated 
with sodium valproate and adjustment of neurotransmitter 
dosage respectively. She has intellectual disability, mild 
Case 1 Case 2 Case 3
Gender Female Female Female
Age at diagnosis 7 months 1 month 3 months
Initial presentation Hypotonia Asymptomatic Hypotonia
Mutation in PTS gene c.242A>G:p.E81A c.166_168del:p.56_56del c.166_168del:p.56_56del
Primary amenorrhea Present Present Present
Galactorrhea Absent Absent Absent
Serum Prolactin 
(ref. 3.4-24µg/L)     350-730 300-568 296-500
Serum FSH  (IU/L) <0.1 1.1 5
Serum LH  (IU/L) <0.1 1.5 3.3
Serum estrogen (pmol/L) 94 69 46
Serum TSH (ref. mU/L) 2.1 0.83 2.2
CSF studies: (on treatment)
5HIAA (ref.67-140 nmol/L) 263 220 -
HVA (ref. 145-324 nmol/L) 649 549 -
Phenylalanine (ref.13-17µmol/L) 13 12 -
Table 1: Clinical and biochemical characteristics of patients
FSH: follicle stimulating hormone; LH: leutinising hormone; TSH: thyroid stimulating hormone; HVA: homovanillic acid; 5HIAA: 
5-hydroxyindolacetic acid
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Figure 1: Magnetic resonance imaging of pituitary gland
 a: Coronal T2-weighted image in patient 1 shows a small T2 hyperintense lesion in the left inferior aspect of the pituitary gland suggestive 
of a microadenoma (arrow), b: coronal dynamic postcontrast T1-weighted image in patient 2 shows a small rounded hypoenhancing lesion 
in the left aspect of the pituitary gland compatible with a microadenoma, c: coronal T2-weighted image in patient 3 shows a small T2 
hyperintense lesion in the right side of the pituitary gland compatible with a microadenoma (arrow). d: coronal postcontrast T1-weighted 
image in patient 3 demonstrates the corresponding hyperenhancement in relation to the remainder of the gland (arrow). 
gland MRI showed a 5 mm size microadenoma (Figure 
1b). She was seen by the endocrinologist and received 
cabergoline 0.5mg twice per week for eight months. 
Prolactin concentrations normalized (6.4 µg/L), and 
menstrual periods started.  She has been started on 
alendronate as her bone densitometry scan showed 
osteoporosis. 
Case 3
A 26-year-old female was diagnosed as having PTPS 
deficiency at the age of three months and was started 
on replacement therapy. She has a mild intellectual 
disability, severe attention deficit hyperactive disorder 
and behavioral problems. She was noted to have high 
prolactin (296 µg/L) at the age of 16 years. MRI scan of 
pituitary gland did not show any focal lesion. Following 
increment in the L-Dopa dosage, prolactin concentration 
initially reduced to 47.8 µg/L, then rose to 257 µg/L in 
a few months. She was seen by the gynecologist at age 
20 years, for primary amenorrhea. Serum prolactin 
levels were high with secondary hypogonadotropic 
hypogonadism (Table 1). She was started on cabergoline 
0.5 mg twice weekly, later increasing to 1 mg twice 
weekly. Serum prolactin levels fell (6 µg/L), and she 
started menstruating. Cabergoline was stopped after 
ten months and was treated with hormone replacement 
therapy (HRT; progyluton) for bone protection and 
regular menstruation. A year later, she was commenced 
on escitalopram because of psychiatric problems. 
Subsequent prolactin concentration after six months was 
475 µg/L, in the presence of regular menstruation. MRI 
scan of the pituitary gland showed 3 mm microadenoma 
(Figure 1c, d). She was again prescribed cabergoline for 
12 weeks by the gynecologist and prolactin levels came 
down to 89 µg/L. She was seen by the endocrinologist 
and was treated with HRT alone as she continued to have 
regular menstrual periods. Her latest prolactin on HRT 
is 161 µg/L. Repeat pituitary gland MRI after three years 
demonstrated an unchanged microadenoma.
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Discussion
Hyperprolactinemia due to dopamine deficiency is 
common in patients with PTPS deficiency. Serum prolactin 
is used as an index of dopaminergic homeostasis and 
is an effective tool for monitoring and optimizing the 
dopaminergic replacement in PTPS deficiency. Patients are 
treated with L-Dopa in divided doses varying between 7-12 
mg/kg body weight daily. Serum prolactin concentrations 
are measured three hours after the administration of 
L-Dopa to assess dopaminergic activity and therapeutic 
control.
Our adult cohort of 27 patients with PTPS deficiency 
consists of 16 females and 11 males. Hyperprolactinemia 
was observed in 10 females (range:45-100 µg/L in six 
and >200 µg/L in four females) and three males (range: 
40-100 µg/L). Prolactin levels normalized in all male and 
four female patients following optimization of L-Dopa 
replacement. In the remaining six female patients, only 
the three patients described here had, persistent marked 
hyperprolactinemia which resulted in secondary hypo-
gonadotrophic hypogonadism, manifesting as primary 
amenorrhea, delayed poor development of secondary 
sexual characters and osteoporosis. All were compliant 
with high dose L- Dopa replacement and in the two 
patients in whom CSF examination was undertaken, it 
confirmed adequate replacement with neurotransmitters 
(Table 1). Pituitary MRI demonstrated the presence 
of microadenoma in all patients. Since other causes of 
hyperprolactinemia including macroprolactinemia (Table 
2) were excluded, we suggest that these patients had 
concurrent microprolactinomas.
Prolactinomas are the most common pituitary 
adenomas which account for 50-60% of all pituitary 
tumors9. They are largely microprolactinomas (less 
than 1 cm in size) which are much common in females. 
Microprolactinomas may remain silent or cause symptoms 
related to hyperprolactinemia such as oligo/amenorrhea, 
galactorrhea and infertility in premenopausal women. 
Diagnosis of prolactinoma is based on the presence of 
hyperprolactinemia with radiological evidence of pituitary 
adenoma. The degree of hyperprolactinemia generally 
correlates with prolactinoma size. Prolactin concentration 
is usually100 to 250 µg/L in microprolactinomas 9 but such 
values are not absolute 10 and may range from 32 to 525 
µg/L 11.
Prolactinoma has not been reported before in patients 
with PTPS deficiency. The diagnosis of prolactinoma 
in these patients could be delayed by the overlap of 
concomitant hyperprolactinemia seen in partially L-Dopa 
supplemented patients. If patient is compliant with optimal 
L-Dopa dosage and prolactin levels remain significantly 
high, we suggest it is important to exclude other causes of 
hyperprolactinemia including concurrent prolactinoma by 
pituitary imaging. In these patients, serum prolactin will be 
an unreliable indicator of L-Dopa replacement. 
They had no other features to suggest that prolactinoma 
was related to genetic syndromes such as multiple 
endocrine neoplasia type 1(MEN1) or familial isolated 
pituitary adenoma (FIPA). The prolactin concentrations 
in these three patients were higher than expected for the 
size of pituitary adenoma. The presence of microadenoma 
in these adequately replaced patients is, however, 
significant and consistent with a microprolactinoma as 
it is well recognized that L-Dopa fails to suppress serum 
prolactin in prolactinomas12. Treatment with cabergoline 
normalised serum prolactin and initiated the menstrual 
cycle, and following withdrawal of cabergoline therapy the 
hyperprolactinemia has recurred. Since the restoration 
of fertility was not the goal of treatment in these adults, 
further treatment with cabergoline was not deemed 
necessary at this stage. 
In summary, persistent hyperprolactinemia despite 
Physiological
Non-pathological
Pregnancy, lactation, nipple stimulation, stress, exercise 
Macroprolactinemia
Pharmacological Antipsychotics- Phenothiazines, haloperidol, risperidone, clozapine, olanzapine
Antidepressants- Tricyclics monoamine oxidase inhibitors, selective serotonin reuptake 
inhibitors
Antihypertensives – Verapamil, reserpine, methyldopa
Antiemetics - Metoclopramide, domperidone, 
H2 blockers: Cimetidine, ranitidine
Pathological (Hypothalamic and pituitary lesions) Prolactinoma, non-functioning pituitary adenoma causing stalk effect
Lymphocytic hypophysitis
Craniopharyngioma, Meningioma, Germinoma, empty sella syndrome
Infiltrative diseases- Sarcoidosis, Histiocytosis X, Tuberculosis, Metastasis
Other diseases
Primary hypothyroidism, chronic renal failure liver cirrhosis, ectopic secretion of 
prolactin Chest-wall lesions (trauma, surgery, herpes zoster virus), polycystic ovarian 
syndrome, seizures
Table 2: Causes of hyperprolactinemia
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adequate L-Dopa replacement should prompt investigation 
for other causes of hyperprolactinemia including 
prolactinoma. Serum prolactin may be an unreliable 
marker of adequacy of L-Dopa replacement therapy in co-
incidental microprolactinomas. 
 Future studies are required to better understand the 
precise mechanisms of action of dopamine, dopamine 
receptors and their effect on prolactin gene expression in 
the pathophysiology of the development of prolactinoma 
in these patients with disproportionately high prolactin 
concentrations as compared to the size of adenoma, 
especially in the background of adequate replacement with 
dopaminergic neurotransmitters. 
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